查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990265

胃腸道糞便檢驗市場：按檢測類型、技術、應用和最終用戶分類 - 2026-2032年全球市場預測

GI Stool Testing Market by Test Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，消化器官系統(GI)糞便檢驗市場價值將達到 7.3952 億美元，到 2026 年將成長至 7.8558 億美元，到 2032 年將達到 11.8368 億美元，複合年成長率為 6.95%。

主要市場統計數據
基準年 2025 7.3952億美元
預計年份：2026年 7.8558億美元
預測年份 2032 1,183,680,000 美元
複合年成長率 (%) 6.95%

展望未來，闡述技術創新、臨床應用、監管更新和以患者為中心的檢體採集模式如何改變消化器官系統糞便診斷。

消化器官系統糞便檢驗已從一項小眾檢查室檢測發展成為一個應用廣泛的診斷領域，其臨床應用不斷拓展，技術也日新月異。分子診斷和定序平台的最新進展提高了檢測的敏感度和特異性，而檢體穩定化、居家採集試劑盒和數位化結果報告的創新則改變了臨床醫生和患者參與檢測過程的方式。這些變化使得更廣泛的篩檢項目得以開展，感染疾病診斷更加精準，微生物組分析也更加深入，這對於治療方案製定和轉化研究都大有裨益。

對正在重塑糞便診斷技術發展和部署的技術、臨床應用、報銷和分銷方面的變革性變化進行了深入分析。

糞便診斷領域因技術、臨床和商業性因素的共同作用而發生了變革性變化。即時PCR、數位PCR和等溫擴增等分子檢測方法因其快速、高精度而日益受到重視，而次世代定序技術則能夠更深入地了解微生物組並進行多種病原體的檢測。同時，免疫檢測在許多檢測流程中仍然是可靠且經濟高效的選擇。當採用化學冷光免疫分析、酵素連結免疫檢測（ELISA）或側向層析等形式時，其優勢尤其顯著，這些形式支持分散式檢查。

對 2025 年美國關稅的最新變化如何影響供應鏈、製造商策略、採購選擇以及診斷服務的連續性進行實際分析。

2025年，美國累積關稅調整為依賴跨境供應鏈的診斷設備製造商和試劑供應商帶來了新的成本考量。新增進口關稅主要影響儀器組件、試劑原料以及用於檢體穩定和萃取流程的耗材。這些貿易措施迫使許多供應商重新評估其籌資策略，加快關鍵組件的在地採購，並修訂分銷合約以降低交付風險和不確定性。

有針對性的細分分析，揭示測試類型、臨床應用、技術方法、最終用戶畫像和分銷選項如何相互交織並影響診斷方法的採用。

市場區隔洞察揭示了糞便診斷領域中臨床需求、技術能力和商業性重點的交匯點。根據檢測類型，市場可分為培養、免疫檢測和聚合酵素鏈鎖反應(PCR) 三大類，每種檢測類型對臨床工作流程的影響各不相同。培養是全面分離病原體的關鍵，免疫檢測因其快速篩檢和成本效益而備受青睞，而聚合酵素鏈鎖反應(PCR) 則可實現靶向性強、靈敏度高的病原體檢測。根據應用領域，市場可細分為三個研究方向：癌症篩檢、感染疾病和微生物組分析。這一範圍表明，診斷重點涵蓋了從人群篩檢到急性感染疾病管理，甚至基於微生物組的探索性研究。

從全面的區域觀點，詳細介紹美洲、歐洲、中東和非洲以及亞太市場的醫療保健基礎設施、監管現狀和採用促進因素的差異。

消化器官系統糞便檢驗的區域趨勢反映了全球市場在醫療保健優先事項、法律規範和基礎設施能力方面的差異。在美洲，分子診斷和中心參考檢查室網路的投資，以及完善的報銷機制和健全的診斷研究生態系統，正在推動基於PCR的感染疾病組合和用於微生物組研究的高級定序的臨床應用。在歐洲、中東和非洲（EMEA），由於法規環境和檢查室能力的差異，免疫檢測的應用呈現出分散化和選擇性採用更複雜的分子檢測相結合的局面。跨境合作和統一指南正日益影響檢測的檢驗和部署。

對競爭定位進行策略概述，重點在於平台整合、證據產生、監管策略、供應鏈韌性和分銷靈活性。

糞便診斷領域的競爭格局日益取決於平台廣度、證據產生、監管應對力和供應鏈韌性的交匯點。領先的診斷開發人員和實驗室集團正在投資整合免疫檢測、分子檢測和定序工作流程的綜合產品組合，以滿足更廣泛的臨床應用需求和支付方的要求。從試劑供應合約到與學術機構的共同開發契約等策略夥伴關係，正在加速將研究層面的微生物組學見解轉化為臨床適用產品。

為企業和醫療保健領導者提供可操作的建議，以最佳化糞便診斷領域的產品檢驗、供應鏈彈性、支付方合作和上市時間。

業界領導者若想最大限度地掌握糞便診斷領域的商機，應優先考慮以下三項相互關聯的舉措：首先，根據明確的臨床終點，協調產品開發和檢驗工作，以證明檢測方法如何變革患者管理並降低後續成本。其次，透過供應商多元化、盡可能在本地生產關鍵組件以及建立健全的庫存和交付監控系統，提升供應鏈的靈活性，從而保護營運免受關稅和物流中斷的影響。第三，制定符合終端使用者（如診斷檢查室、醫院、參考實驗室和研究機構）柔軟性的市場推廣策略，並採用多元化的採購管道，結合直銷、線上通路和第三方經銷商。

為了支持研究結果，研究調查方法，包括專家訪談、文獻檢驗、技術比較評估和供應鏈敏感度分析。

本研究整合了訪談、文獻綜述和分析性綜述，旨在對糞便診斷的現狀進行實證評估。透過對實驗室主任、臨床負責人、法規專家、採購經理和技術開發人員的結構化訪談，我們獲得了關鍵見解，從而對糞便診斷的推廣應用促進因素、檢驗重點和運營限制有了定性理解。二級資訊來源包括同行評審的臨床研究、法規指導文件和供應商技術規範，這些資料用於支援對各種技術的性能特徵和監管路徑的分析。

簡明結論總結了臨床效用、技術能力、監管合規性和營運彈性如何決定糞便診斷的成功。

總之，消化器官系統糞便檢驗正處於一個轉折點，技術成熟度、不斷變化的臨床預期和不斷演進的經營模式在此交匯融合。分子診斷和次世代定序正在拓展診斷能力，使其能夠應用於從感染疾病管理到微生物組研究等多種領域。同時，免疫檢測持續提供實用、高通量的篩檢解決方案，支援分散式醫療保健。監管和報銷趨勢正日益成為影響檢測應用的重要因素，而供應鏈韌性正成為應對關稅和物流波動的策略差異化優勢。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 胃腸道糞便檢驗市場：檢測類型

  • 文化
  • 免疫檢測
  • 聚合酵素鏈鎖反應

第9章：胃腸道糞便檢驗市場：依技術分類

  • 免疫檢測
    • 化學冷光免疫檢測
    • ELISA
    • 側向流
  • 微陣列
  • 分子診斷
    • 數位PCR
    • 等溫擴增
    • 即時PCR
  • 次世代定序

第10章：胃腸道糞便檢驗市場：依應用領域分類

  • 癌症篩檢
  • 感染疾病
  • 微生物組分析

第11章 胃腸道糞便檢驗市場：依最終用戶分類

  • 診斷檢查室
  • 醫院
  • 標準檢驗組織
  • 研究機構

第12章 胃腸道糞便檢驗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 胃腸道糞便檢驗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 胃腸道糞便檢驗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國胃腸道糞便檢驗市場

第16章：中國胃腸道糞便檢驗市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton Dickinson & Company
  • Bio-Rad Laboratories
  • bioMerieux Inc.
  • Cardinal Health Inc.
  • Cenogenics Corporation
  • CTK Biotech Inc.
  • Danaher Corporation
  • Diagnostic Solutions Laboratory
  • DiaSorin SpA
  • Doctors Data
  • Epitope Diagnostics Inc.
  • Eurofins
  • Genova Diagnostics
  • Hologic Inc.
  • Meridian Bioscience Inc.
  • Metropolis Healthcare Ltd
  • Qiagen
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Randox Laboratories
  • Roche Diagnostics
  • ScheBo Biotech AG
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-CB04E056547A

The GI Stool Testing Market was valued at USD 739.52 million in 2025 and is projected to grow to USD 785.58 million in 2026, with a CAGR of 6.95%, reaching USD 1,183.68 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 739.52 million
Estimated Year [2026] USD 785.58 million
Forecast Year [2032] USD 1,183.68 million
CAGR (%) 6.95%

A forward-looking introduction explaining how technological innovation, clinical adoption, regulatory updates, and patient-centric collection models are reshaping gastrointestinal stool diagnostics

Gastrointestinal stool testing has evolved from niche laboratory assays into a diverse diagnostic domain with expanding clinical applications and rapidly improving technologies. Recent advances in molecular diagnostics and sequencing platforms have increased analytical sensitivity and specificity, while innovations in sample stabilization, at-home collection kits, and digital result reporting have changed how clinicians and patients engage with testing pathways. These shifts are enabling broader screening programs, more precise infectious disease diagnostics, and richer microbiome analyses that inform both therapeutic decisions and translational research.

As clinical pathways adapt, regulatory frameworks and reimbursement models are responding in parallel, creating new pathways for test validation and market entry. In practice, this means laboratory directors, hospital administrators, and product teams need to integrate operational feasibility with clinical utility when selecting assays and deploying testing workflows. Moving forward, integrating multi-analyte molecular assays with immunoassays and sequencing outputs will be crucial for delivering comprehensive diagnostic insights at the point where clinical decision-making occurs.

An incisive assessment of the transformative technological, clinical adoption, reimbursement, and distribution shifts reshaping how stool diagnostics are developed and deployed

The landscape of stool diagnostics has undergone transformative shifts driven by converging technological, clinical, and commercial forces. Molecular testing modalities, including real time PCR, digital PCR, and isothermal amplification, are increasingly favored for their rapid turnaround and precision, while next generation sequencing has unlocked deeper microbiome insights and multiplex pathogen detection. In tandem, immunoassays remain a robust, cost-effective option for many laboratory workflows, particularly when configured as chemiluminescent immunoassay, Elisa, or lateral flow formats that support decentralized testing.

Clinical practice has shifted toward multiplexed and layered testing strategies that combine culture, immunoassay, and polymerase chain reaction approaches where appropriate, enabling clinicians to triage patients more effectively and reduce empirical therapy. Concurrently, payer interest in tests that demonstrably impact clinical outcomes has intensified, prompting developers to generate evidence that aligns analytical validity with clinical utility. Operationally, distribution models and online ordering platforms are accelerating access, while diagnostic laboratories and hospitals reassess laboratory capacity, reference testing partnerships, and data integration to support these transformative shifts.

A practical analysis of how recent United States tariff changes in 2025 are influencing supply chains, manufacturer strategies, procurement choices, and diagnostic service continuity

In 2025, cumulative tariff adjustments in the United States introduced new cost considerations for diagnostic manufacturers and reagent suppliers that rely on cross-border supply chains. Additional import duties have selectively affected instrument components, raw materials for reagents, and consumables used in sample stabilization and extraction workflows. These trade measures have prompted many suppliers to reassess sourcing strategies, accelerate localization of critical components, and recalibrate distribution agreements to mitigate delivery risks and timeline uncertainty.

Consequently, laboratories and procurement teams have responded by diversifying supplier bases and increasing strategic inventory for high-turnover consumables. Suppliers that maintain flexible manufacturing footprints and visible supply chain telemetry have seen improved resilience, while those dependent on specialized imported components have pursued dual-sourcing or contractual hedges. Importantly, clinical laboratories and healthcare systems are balancing short-term cost pressures with the need to preserve continuity of diagnostic services, making supplier reliability and validation support key decision criteria when selecting partners amidst evolving tariff landscapes.

Targeted segmentation intelligence revealing how test type, clinical application, technological modality, end-user profile, and distribution choices intersect to shape diagnostic adoption

Segmentation insights illuminate where clinical demand, technical capability, and commercial focus intersect across stool diagnostics. Based on Test Type, market is studied across Culture, Immunoassay, and Polymerase Chain Reaction, and each test type influences clinical workflows differently: culture remains essential for comprehensive pathogen isolation, immunoassays are valued for rapid screening and cost efficiency, and polymerase chain reaction enables targeted, high-sensitivity pathogen detection. Based on Application, market is studied across Cancer Screening, Infectious Disease, and Microbiome Analysis, and this spectrum demonstrates how diagnostic priorities extend from population-level screening to acute infectious management and exploratory microbiome-driven research.

Based on Technology, market is studied across Immunoassays, Microarrays, Molecular Diagnostics, and Next Generation Sequencing. The Immunoassays is further studied across Chemiluminescent Immunoassay, Elisa, and Lateral Flow, offering options that balance throughput, sensitivity, and decentralization. The Molecular Diagnostics is further studied across Digital PCR, Isothermal Amplification, and Real Time PCR, each offering trade-offs between quantitative precision, implementation complexity, and time-to-result. Based on End User, market is studied across Diagnostic Laboratories, Hospitals, Reference Laboratories, and Research Institutes, reflecting differing adoption drivers from routine clinical diagnostics to investigational studies. Based on Distribution Channel, market is studied across Direct Sales, Online, and Third Party Distributors, indicating how go-to-market strategies must align with buyer preferences, procurement cycles, and regulatory constraints.

Comprehensive regional perspective detailing how healthcare infrastructure, regulatory realities, and adoption drivers vary across the Americas, EMEA, and Asia-Pacific markets

Regional dynamics in gastrointestinal stool testing reflect differentiated healthcare priorities, regulatory frameworks, and infrastructure capabilities across global markets. In the Americas, investment in molecular diagnostics and centralized reference laboratory networks has driven broader clinical adoption of PCR-based infectious disease panels and advanced sequencing for microbiome studies, supported by established reimbursement pathways and robust diagnostic research ecosystems. In Europe, Middle East & Africa, heterogeneity in regulatory environments and laboratory capacity has led to a mix of decentralized immunoassay adoption and selective implementation of higher-complexity molecular assays, with cross-border collaboration and harmonized guidance increasingly shaping test validation and deployment.

In the Asia-Pacific region, rapid tech adoption, significant private-sector laboratory expansion, and government-backed screening initiatives have accelerated uptake of both point-of-care immunoassays and centralized sequencing capabilities. Across regions, infrastructural differences influence adoption timelines and preferred modalities, while cross-regional partnerships and harmonization efforts are helping to disseminate best practices for clinical validation, sample logistics, and result interoperability. For stakeholders, regional strategy must therefore balance global technology trends with local regulatory realities and laboratory capabilities.

Strategic overview of competitive positioning highlighting platform integration, evidence generation, regulatory strategy, supply chain resilience, and distribution agility

Competitive dynamics in stool diagnostics are increasingly defined by the intersection of platform breadth, evidence generation, regulatory acumen, and supply chain resilience. Leading diagnostic developers and laboratory groups are investing in integrated portfolios that combine immunoassays, molecular tests, and sequencing workflows to serve a broader set of clinical use cases and payer requirements. Strategic partnerships-ranging from reagent supply agreements to co-development arrangements with academic institutions-are accelerating the translation of research-grade microbiome insights into clinically actionable products.

Additionally, companies that offer robust validation datasets, streamlined regulatory submissions, and scalable manufacturing capacity gain preferential access to large institutional buyers and reference laboratory networks. Distribution strategy also plays a pivotal role; organizations that provide flexible procurement options, including online ordering and third party distribution networks, are better positioned to meet the needs of diverse end users. Ultimately, competitive advantage increasingly depends on the ability to demonstrate clinical utility, support implementation through training and validation, and maintain transparent, resilient supply chains.

Actionable recommendations for companies and healthcare leaders to optimize product validation, supply chain resilience, payer engagement, and go-to-market execution in stool diagnostics

Industry leaders seeking to capitalize on stool diagnostic opportunities should prioritize three interrelated actions: first, align product development and validation efforts with clear clinical endpoints that demonstrate how tests change patient management and reduce downstream costs. Second, invest in supply chain flexibility by diversifying suppliers, localizing critical component production where feasible, and instituting robust inventory and delivery monitoring to insulate operations from tariff and logistics disruptions. Third, design go-to-market strategies that reflect end-user needs across diagnostic laboratories, hospitals, reference laboratories, and research institutes, and that leverage a mix of direct sales, online channels, and third party distributors to reach diverse procurement pathways.

In addition, stakeholders should strengthen payer engagement early in clinical development to clarify evidence thresholds for reimbursement, and they should pursue interoperability standards and data integration capabilities to ensure results are actionable within electronic health records and laboratory information management systems. Finally, consider strategic partnerships with clinical networks and research consortia to accelerate real-world evidence generation and validate microbiome and cancer screening applications in representative patient populations. Taken together, these steps reduce commercial risk and enhance the probability of sustainable clinical adoption.

Transparent research methodology outlining expert interviews, literature triangulation, comparative technology assessment, and supply chain sensitivity analysis to underpin findings

This research synthesizes primary interviews, secondary literature, and analytical review to produce an evidence-driven assessment of the stool diagnostics landscape. Primary insights were derived from structured interviews with laboratory directors, clinical leaders, regulatory specialists, procurement managers, and technology developers, which informed qualitative understanding of adoption drivers, validation priorities, and operational constraints. Secondary sources included peer-reviewed clinical studies, regulatory guidance documents, and supplier technical specifications to corroborate performance characteristics and regulatory pathways for different technologies.

Analytical methods included comparative technology assessment, supply chain sensitivity analysis, and a structured mapping of clinical use cases to test modalities and end-user workflows. Where possible, validation claims and performance metrics reported by manufacturers were cross-checked against independent literature and expert feedback. Throughout the methodology, emphasis was placed on transparency of data sources and reproducibility of key analytic steps, and sensitivity considerations were used to contextualize where findings depend on evolving regulatory or reimbursement decisions.

A concise conclusion synthesizing how clinical utility, technological capability, regulatory alignment, and operational resilience will determine success in stool diagnostics

In conclusion, gastrointestinal stool testing is at an inflection point where technological maturation, shifting clinical expectations, and evolving commercial models converge. Molecular diagnostics and next generation sequencing are broadening diagnostic capabilities and enabling multipurpose applications ranging from infectious disease management to microbiome-informed research, while immunoassays continue to deliver pragmatic, high-throughput screening solutions that support decentralized care. Regulatory and reimbursement developments are increasingly important determinants of adoption, and supply chain resilience has emerged as a strategic differentiator in the wake of tariff and logistics volatility.

Moving forward, successful stakeholders will be those that align rigorous validation and evidence generation with operational readiness and flexible distribution strategies. Collaboration across clinicians, laboratory partners, and technology providers will accelerate adoption and ensure that diagnostic innovations translate into measurable improvements in patient care. In short, integrated approaches that balance clinical utility, implementation feasibility, and commercial agility will define success in this rapidly evolving diagnostic category.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. GI Stool Testing Market, by Test Type

  • 8.1. Culture
  • 8.2. Immunoassay
  • 8.3. Polymerase Chain Reaction

9. GI Stool Testing Market, by Technology

  • 9.1. Immunoassays
    • 9.1.1. Chemiluminescent Immunoassay
    • 9.1.2. Elisa
    • 9.1.3. Lateral Flow
  • 9.2. Microarrays
  • 9.3. Molecular Diagnostics
    • 9.3.1. Digital PCR
    • 9.3.2. Isothermal Amplification
    • 9.3.3. Real Time PCR
  • 9.4. Next Generation Sequencing

10. GI Stool Testing Market, by Application

  • 10.1. Cancer Screening
  • 10.2. Infectious Disease
  • 10.3. Microbiome Analysis

11. GI Stool Testing Market, by End User

  • 11.1. Diagnostic Laboratories
  • 11.2. Hospitals
  • 11.3. Reference Laboratories
  • 11.4. Research Institutes

12. GI Stool Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. GI Stool Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. GI Stool Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States GI Stool Testing Market

16. China GI Stool Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Becton Dickinson & Company
  • 17.7. Bio-Rad Laboratories
  • 17.8. bioMerieux Inc.
  • 17.9. Cardinal Health Inc.
  • 17.10. Cenogenics Corporation
  • 17.11. CTK Biotech Inc.
  • 17.12. Danaher Corporation
  • 17.13. Diagnostic Solutions Laboratory
  • 17.14. DiaSorin S.p.A.
  • 17.15. Doctors Data
  • 17.16. Epitope Diagnostics Inc.
  • 17.17. Eurofins
  • 17.18. Genova Diagnostics
  • 17.19. Hologic Inc.
  • 17.20. Meridian Bioscience Inc.
  • 17.21. Metropolis Healthcare Ltd
  • 17.22. Qiagen
  • 17.23. Quest Diagnostics Incorporated
  • 17.24. QuidelOrtho Corporation
  • 17.25. Randox Laboratories
  • 17.26. Roche Diagnostics
  • 17.27. ScheBo Biotech AG
  • 17.28. Siemens Healthineers
  • 17.29. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL GI STOOL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GI STOOL TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GI STOOL TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GI STOOL TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GI STOOL TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GI STOOL TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES GI STOOL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA GI STOOL TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GI STOOL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GI STOOL TESTING MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GI STOOL TESTING MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GI STOOL TESTING MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GI STOOL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GI STOOL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GI STOOL TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GI STOOL TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GI STOOL TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GI STOOL TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GI STOOL TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GI STOOL TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GI STOOL TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GI STOOL TESTING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GI STOOL TESTING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GI STOOL TESTING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GI STOOL TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GI STOOL TESTING MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GI STOOL TESTING MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GI STOOL TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GI STOOL TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GI STOOL TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GI STOOL TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GI STOOL TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GI STOOL TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GI STOOL TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GI STOOL TESTING MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GI STOOL TESTING MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GI STOOL TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GI STOOL TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GI STOOL TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GI STOOL TESTING MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GI STOOL TESTING MARKET SIZE, BY CANCER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GI STOOL TESTING MARKET SIZE, BY CANCER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GI STOOL TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GI STOOL TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GI STOOL TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GI STOOL TESTING MARKET SIZE, BY MICROBIOME ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GI STOOL TESTING MARKET SIZE, BY MICROBIOME ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GI STOOL TESTING MARKET SIZE, BY MICROBIOME ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GI STOOL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GI STOOL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GI STOOL TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GI STOOL TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GI STOOL TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GI STOOL TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GI STOOL TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GI STOOL TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GI STOOL TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GI STOOL TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GI STOOL TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GI STOOL TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GI STOOL TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS GI STOOL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA GI STOOL TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GI STOOL TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. GCC GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GCC GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. GCC GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. GCC GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. G7 GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. G7 GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. G7 GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 158. G7 GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. G7 GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. G7 GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. NATO GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. NATO GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. NATO GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 165. NATO GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 166. NATO GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. NATO GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL GI STOOL TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES GI STOOL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA GI STOOL TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA GI STOOL TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA GI STOOL TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA GI STOOL TESTING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA GI STOOL TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA GI STOOL TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA GI STOOL TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)